NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Imuran Dosing in Crohn's Disease Study
Phase 2
Terminated
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2005-06-09
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 50
- Registration Number
- NCT00113503
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Long Island Clinical Research Assoc., Great Neck, New York, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00113373
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the BladderDistal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerRegional Transitional Cell Cancer of the Renal Pelvis and UreterSquamous Cell Carcinoma of the BladderStage III Bladder Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00112905
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1
Completed
- Conditions
- Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Diffuse AstrocytomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Pilocytic AstrocytomaAdult Mixed GliomaAdult Pineal Gland AstrocytomaAdult Subependymal Giant Cell Astrocytoma
- Interventions
- Other: pharmacological studyProcedure: therapeutic conventional surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT00112736
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase 1
Completed
- Conditions
- Stage IV Renal Cell CancerClear Cell Renal Cell CarcinomaRecurrent Renal Cell Cancer
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00112840
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1
Terminated
- Conditions
- Adult Lymphocyte Predominant Hodgkin LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2016-08-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00112723
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00112684
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Phase 2
Terminated
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- Procedure: therapeutic conventional surgeryOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00112866
- Locations
- 🇺🇸
North American Brain Tumor Consortium, Watertown, Massachusetts, United States
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00112853
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Recurrent MelanomaRecurrent Renal Cell CancerStage IV MelanomaStage IV Renal Cell CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00112476
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States